2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
- PMID: 36017568
- DOI: 10.1093/eurheartj/ehac244
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Erratum in
-
Erratum to: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC).Eur Heart J. 2023 May 7;44(18):1621. doi: 10.1093/eurheartj/ehad196. Eur Heart J. 2023. PMID: 36952225 No abstract available.
Keywords: Amyloid light-chain cardiac amyloidosis; Androgen deprivation therapy; Anthracycline; Arrhythmias; Atrial fibrillation; Biomarkers; Cancer; Cancer survivors; Carcinoid syndrome; Cardiac magnetic resonance; Cardiac tumour; Cardio-oncology; Cardiotoxicity; Chemotherapy; Coronary artery disease; Echocardiography; Fluoropyrimidine; Guidelines; Haematopoietic stem cell transplantation; Heart failure; Hormone therapy; Hypertension; Immunotherapy; Ischaemic heart disease; Myocarditis; Pericardial disease; Proteasome inhibitors; Pulmonary hypertension; QTc prolongation; Radiotherapy; Risk stratification; Strain; Thrombosis; Trastuzumab; Valvular heart disease; Vascular endothelial growth factor inhibitors (VEGFi); Venous thromboembolism.
Comment in
-
First European Society of Cardiology Cardio-Oncology Guidelines: A Big Leap Forward for an Emerging Specialty.Heart Lung Circ. 2022 Dec;31(12):1563-1567. doi: 10.1016/j.hlc.2022.11.003. Heart Lung Circ. 2022. PMID: 36549840 No abstract available.
-
Cardio-oncology: a new field requiring guidance.Eur Heart J Cardiovasc Imaging. 2023 Feb 17;24(3):e47. doi: 10.1093/ehjci/jeac250. Eur Heart J Cardiovasc Imaging. 2023. PMID: 36572979 No abstract available.
-
A call for harmonized surveillance recommendations in cardio-oncology.Eur Heart J. 2023 Aug 14;44(31):3017-3018. doi: 10.1093/eurheartj/ehad268. Eur Heart J. 2023. PMID: 37350756 No abstract available.
-
Harmonizing the cardiovascular care of adult patients with cancer.Eur Heart J. 2023 Aug 14;44(31):3019-3020. doi: 10.1093/eurheartj/ehad267. Eur Heart J. 2023. PMID: 37351594 No abstract available.
Similar articles
-
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).Eur Heart J Cardiovasc Imaging. 2022 Sep 10;23(10):e333-e465. doi: 10.1093/ehjci/jeac106. Eur Heart J Cardiovasc Imaging. 2022. PMID: 36017575 No abstract available.
-
[2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)].G Ital Cardiol (Rome). 2023 Feb;24(2 Suppl 1):e1-e130. doi: 10.1714/3967.39463. G Ital Cardiol (Rome). 2023. PMID: 36853174 Italian. No abstract available.
-
Erratum: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC).Eur Heart J Cardiovasc Imaging. 2023 May 31;24(6):e98. doi: 10.1093/ehjci/jead080. Eur Heart J Cardiovasc Imaging. 2023. PMID: 37076917 No abstract available.
-
[The Cardio-Oncology Guideline - A Comprehensive Approach to Managing Cardiovascular Risks in Cancer Patients].Dtsch Med Wochenschr. 2024 Jun;149(12):719-723. doi: 10.1055/a-2104-6363. Epub 2024 May 23. Dtsch Med Wochenschr. 2024. PMID: 38781996 Review. German.
-
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.CA Cancer J Clin. 2016 Jul;66(4):309-25. doi: 10.3322/caac.21341. Epub 2016 Feb 26. CA Cancer J Clin. 2016. PMID: 26919165 Review.
Cited by
-
Ibrutinib Promotes Atrial Fibrillation by Disrupting A-Kinase Anchoring Protein 1-Mediated Mitochondrial Quality Surveillance in Cardiomyocytes.Research (Wash D C). 2024 Oct 29;7:0509. doi: 10.34133/research.0509. eCollection 2024. Research (Wash D C). 2024. PMID: 39469220 Free PMC article.
-
Management of a Rare Mitral Valve Sarcoma Requiring Valve Replacement and Chemotherapy.JACC Case Rep. 2024 Aug 21;29(16):102474. doi: 10.1016/j.jaccas.2024.102474. eCollection 2024 Aug 21. JACC Case Rep. 2024. PMID: 39295791 Free PMC article.
-
Arterial Thrombosis in Patients with Cancer.Cancers (Basel). 2024 Jun 17;16(12):2238. doi: 10.3390/cancers16122238. Cancers (Basel). 2024. PMID: 38927943 Free PMC article. Review.
-
Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea.Sci Rep. 2023 Dec 8;13(1):21756. doi: 10.1038/s41598-023-48678-1. Sci Rep. 2023. PMID: 38066029 Free PMC article.
-
Sodium-Glucose Cotransporter 2 Inhibitors During Cancer Therapy: Benefits, Risks, and Ongoing Clinical Trials.Curr Oncol Rep. 2024 Oct;26(10):1188-1196. doi: 10.1007/s11912-024-01577-8. Epub 2024 Jul 11. Curr Oncol Rep. 2024. PMID: 38990501 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical